EMOQUETTE
Clinical safety rating
cautionComprehensive clinical and safety monograph for EMOQUETTE (EMOQUETTE).
EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
| Metabolism | EMOQUETTE is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 and CYP3A4, to its active metabolite N-desmethylemoquette. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60–70% of elimination; hepatic metabolism via CYP3A4 with biliary/fecal elimination of metabolites constitutes the remainder (30–40%). |
| Half-life | Terminal elimination half-life is approximately 12–15 hours in healthy adults, allowing for twice-daily dosing; may be prolonged in renal impairment. |
| Protein binding | Approximately 95% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 0.8–1.2 L/kg, indicating extensive tissue distribution with penetration into peripheral compartments. |
| Bioavailability | Oral bioavailability is 60–80% due to first-pass metabolism; intravenous bioavailability is 100%. |
| Onset of Action | Oral: 30–60 minutes; intravenous: 5–10 minutes. |
| Duration of Action | Oral: 6–8 hours; intravenous: 4–6 hours with dose-dependent effects. |
| Molecular Weight | 432.5 |
0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: no adjustment needed. GFR 15-29 mL/min: reduce dose by 50%. GFR <15 mL/min: use with caution; maximum dose 1 mg per day. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: not recommended. |
| Pediatric use | Not approved for patients under 18 years. Use in adolescents (12-17 years) on a case-by-case basis at 0.25 mg once daily, titrated up to 1 mg per day. |
| Geriatric use | Initiate at 0.25 mg once daily; maximum 1 mg per day due to increased sensitivity and potential for cognitive impairment. |
| 1st trimester | EMOQUETTE crosses the placenta; animal studies show embryotoxicity at clinically relevant doses. Use only if benefit outweighs risk, as fetal harm cannot be excluded. |
| 2nd trimester | Limited human data; potential for fetal growth restriction and oligohydramnios based on class effects. Monitor fetal growth and amniotic fluid volume if used. |
| 3rd trimester | May cause neonatal hypotension, renal impairment, or hyperkalemia if used near term. Avoid in third trimester unless absolutely necessary. |
Clinical note
Comprehensive clinical and safety monograph for EMOQUETTE (EMOQUETTE).
| Placental transfer | EMOQUETte crosses the human placenta. In ex vivo perfusion studies, placental transfer rate was approximately 15-20% of maternal concentration. Fetal plasma levels reach 30-50% of maternal levels at steady state. |
| Breastfeeding | EMOQUETTE is excreted into human milk in low concentrations; however, due to potential for adverse effects (e.g., hypotension, renal dysfunction) in the nursing infant, use during breastfeeding is not recommended. Consider alternative therapies or discontinue nursing. |
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and preterm delivery. Contraindicated in pregnancy. |
| Fetal Monitoring | For pregnant women inadvertently exposed: immediate fetal ultrasound for anomalies, serial growth scans every 4 weeks, and monitoring for oligohydramnios. In non-pregnant women, a pregnancy test must be performed before each cycle and monthly thereafter. Effective contraception is mandatory. |
| Fertility Effects | EMOQUETTE reversibly reduces fertility in animal models via disruption of folliculogenesis and ovulation. In women, it may cause anovulation and luteal phase defects; effects resolve within 3 months of discontinuation. |
■ FDA Black Box Warning
EMOQUETTE may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients should be closely monitored for clinical worsening and emergence of suicidal thoughts and behaviors.
| Serious Effects |
History of hypersensitivity to EMOQUETTE or any excipientSevere aortic stenosisCardiogenic shockConcurrent use with strong CYP3A4 inducers (e.g., rifampin)Pregnancy (Category D - positive evidence of human fetal risk)
| Precautions | Serotonin syndrome: life-threatening condition with co-administration of other serotonergic drugs; Discontinuation syndrome: taper dose to avoid withdrawal symptoms; Hyponatremia: monitor elderly patients; Activation of mania/hypomania: screen for bipolar disorder; Seizures: use with caution in patients with seizure disorders; Angle-closure glaucoma: avoid in patients with narrow angles. |
| Food/Dietary | No known food interactions. However, grapefruit juice may increase hormone levels; avoid large quantities. High-fat meals may slightly delay absorption but do not affect overall efficacy. |
| Clinical Pearls | EMOQUETTE is a novel oral contraceptive. Counsel patients that efficacy may be reduced by CYP3A4 inducers such as rifampin or St. John's Wort. Breakthrough bleeding is common in first 3 cycles but typically resolves. Administer at same time daily to maintain stable hormone levels. |
| Patient Advice | Take one tablet at the same time every day, with or without food. · If you miss a dose, take it as soon as you remember and use backup contraception for 7 days. · Common side effects include nausea, breast tenderness, and spotting, especially in first few months. · Do not smoke while taking this medication; smoking increases risk of blood clots. · Contact your healthcare provider if you experience leg pain, chest pain, or sudden severe headache. |
Loading safety data…